THE CAPITAL-NCD-NEXUS: THE COMMERCIAL DETERMINANTS OF HEALTH AND GLOBAL CAPITAL FLOWS

By: Christian Franz and Ilona Kickbusch

Summary: In the past, the role of global capital flows for health has not been considered in the debate about key risk factors of Noncommunicable Diseases (NCDs). This is a blind spot in public health. A significant share of the global food and beverage industry is owned by institutional investors. Cross-border mergers and acquisition volumes in the food, beverage, and tobacco industries have substantially increased. Progress on preventing and controlling NCDs requires the public health community to engage in a forward-looking discussion to address investors’ responsibility in relation to global health in general and the tsunami of NCDs in particular.

Keywords: NCDs, Public Health, Global Capital Flows, Commercial Determinants of Health, Obesity, Institutional Investors

Introduction

“[…] how can food and soft drink makers market and sell their products to the masses of children around the world, seeing them more as opportunities for profit, and turning a blind eye to the spiralling rates of childhood obesity and early onset diabetes?” When World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus asked this question in his opening remarks at the Global Conference on NCDs in Montevideo 2017, his words must have resonated with most attending Ministers of Health. Globally, the number of obese children and youths was estimated to have reached more than 107 million in 2015 – 30 million more than 15 years earlier and a 1.1 percentage point increase in prevalence.

Out of 51 countries in the WHO European Region, in 42 countries, obesity among children and youth has increased (see Figure 1). In absolute numbers these developments appear even more dramatic:
since 2000, the number of obese adults has increased by 38 million. The number of obese children rose by 1.5 million.

Commercial determinants of health and NCDs

Dr Ghebreyesus’ remarks also reflect a new perspective on the role of private sector firms: in a global consumer society, economic actors are increasingly considered as health actors. If corporations promote and sell products that are potentially harmful to health, the argument that consumers can decide for themselves does not resonate to the same extent.

Certainly, public health analysis has always looked at the power of corporations – especially in the field of tobacco, but only more recently has it started to include other sectors in a more systematic way by discussing “unhealthy commodities”, “industrial epidemics”, “profit-driven epidemics”, and corporate practices harmful to health. This type of analysis is concerned with “risks inherent from consumption of, or exposure to, commercial products – such as ultra-processed foods and beverages, tobacco and alcohol” [emphasis added by the authors].

Proposed as a concept to unify such perspectives, the banner of the ‘commercial determinants of health (CDoH)’ suggests the systematic analysis of drivers and channels by which corporations have an impact on the NCDs.
CDoH are defined as “strategies and approaches used by the private sector to promote products and choices that are detrimental to health”. This single concept comprises a number of others: at the micro level, these include consumer and health behaviour, individualisation, and choice; at the macro level, the global risk society, the global consumer society, and the political economy of globalisation.

One of the key drivers identified within the CDoH is the internationalisation of trade, capital and information flows. Higher degrees of trade openness, as well as global media access, allow companies to reach more customers with their marketing messages and their products. Higher trade volumes can also come with a higher dependence on foreign products, changing food diets, and potentially less influence of national policies to shape food supply chains. The dynamic behind this driver is astonishing: in 2016 goods and services worth US$ 22 trillion were imported around the world – up from US$ 7.9 trillion in 2000 and an equivalent of 28% of global gross domestic product (GDP). While the effects of trade on health have been subject to much research, there is yet little understanding of the impact of global capital flows on health and the risk factors driving NCDs.

**The relevance of global investors**

There are various ways in which global capital flows can affect industries relevant for NCD risk factors. While those might differ from industry to industry, the following four general aspects give an idea of the terrain:

(1) **Ownership:** CEOs and other corporate officers are responsible for their business strategies and the impact their business activity has on stakeholders. In the end, however, the true accountability lies with the owners of that business, i.e., the shareholders.

(2) **Industry specifics:** Large food, beverage, and tobacco firms are among the most internationalised businesses in the entire economy. While national regulation and cultural characteristics play a vital role for the final consumption basket, global sourcing strategies imply a heavy reliance on inputs from various countries and sectors. Economies of scale are an important factor in the profitability of food, wholesale, retail, and beverage firms, which usually have low margins per product sold. The setup of a global supply and production chain is a capital-intensive endeavour. Ideally, one product can be sold across countries without much customisation.

(3) **Concentration:** Global investment activity can lead to or accelerate market concentration in countries or entire economic regions. International investors that actively manage their investments (such as private equity firms) have a great incentive to utilise synergies between their investments across sectors and countries. National competitors might see themselves confronted by multinational enterprises backed by international capital.

(4) **Leverage:** Addressing the source of funding of firms – be it through equity (e.g. the selling of stocks) or through debt (e.g. loans of banks) – represents a potentially powerful lever to alter industry-wide business practices and strategies. It is this angle that triggered large divestment campaigns over the past 40 years in tobacco.

Given the list above, there is immense ground work to be done among public health experts. Too little is known about the scale at which global capital plays a role within the food, beverage, and tobacco industries in different countries. Moreover, it is not just the ‘how much’ which plays a role. For any political strategy it is relevant to ask about the actors. Pension funds, investment firms, insurers, and banks...
are active around the world shifting the savings of billions of people from portfolio to portfolio in order to maximise profits for the firm and savers. There will be differences across sectors. Some sectors and their key players might not be publicly traded, but rather owned by entrepreneurs themselves or wealthy individuals.

Finally, it is important to ask how to leverage owners’ power over their firms for the fight against NCDs. The platform on which public health advocates speak to sovereign wealth funds will likely have to be different from private equity funds. And the strategy for the tobacco industry cannot be the same as with global food conglomerates.

The volume of global capital flows into food, beverage, and tobacco

In 2017, global foreign direct investments (FDI) into countries amounted to US$ 1.4 trillion. Cross-border mergers and acquisitions (M&As) are an important part of FDIs in this context, because such transactions represent a “lasting interest”* in foreign enterprises (e.g. voting power or market access). M&As also imply that investors purchase existing business assets in the country (be it to incorporate or replace that business infrastructure). In 2017, such cross-border M&A purchases were estimated to have reached more than US$ 690 billion.

The 2017 transaction value of cross-border M&As in food, beverage, and tobacco amounted to more than US$ 75 billion (see Figure 2, left panel) which represented approximately 11% of the total value of cross-border M&As. What is striking is not only the dramatic spike in M&A volumes in the past two years, but also the increased share of M&As in those sectors since 2010 (see Figure 2, right panel). Clearly, over the past seven years, international capital has become a more important factor in these sectors.

The role of institutional investors

Institutional investors such as pension funds, insurance firms, and investment funds are key actors behind transnational capital flows. In OECD-countries alone institutional investors have assets worth US$ 92 trillion under management (US$ 5 trillion in emerging economies). Among them are gigantic OECD-region-based pension funds which have around US$ 28 trillion worth of assets under management – an equivalent of 56% of the group’s GDP.

A possible way to get an idea of the power of institutional investors in relevant sectors is to look at their ownership in publicly traded corporations around the world. Companies are obliged to report not only their capital stock, but also how much of the shares are held by institutional investors, company officers, and insiders. This information is used in Figure 3.
which plots the share of the stocks of corporations in the sector that is held by institutional investors for different regional averages.

The first relevant finding is that overall levels of institutional investor shares in firms of the selected sectors vary tremendously across sectors and regions. But in the US and Europe, the share of institutional investors is at least 20% in all selected sectors. A key reason behind the variation is the difference in how investments are intermediated and which investment products are preferred by institutional investors. Institutional investors generally play a much more important role for equity markets in the US than in Europe or most emerging economies.

In US, the growing share of institutional investors in food processing and food wholesalers is not only quite dynamic, but also robust. Before the end of the 2000s the average shares held by such investors in both sectors hovered between 20–30%. This changed dramatically in the years that followed: in 2016, more than 65% of the publicly traded food wholesalers and about 55% of the food processing industry were owned by mutual funds, pension funds and other institutional investors. A similarly strong effect is not visible, however, for the other regions – nor on the global scale.

Lastly, ownership of beverage firms – both alcoholic and soft drinks – lies less with institutional investors and has remained quite unchanged. An exception is the increase in ‘institutional ownership’ among American alcoholic beverage firms which has reached about 40%. This last finding is interesting given the immense concentration in the crafts beer market in the US over the few past years – driven by the big market incumbents who reacted to the wave of new product innovations in the market.

Conclusions

Given Dr Ghebreyesus’ supportive statements in Montevideo it was surprising that the Draft Political Declaration for the upcoming UN High-Level Meeting on NCDs has fallen short on bold suggestions on how to prevent and control NCDs.

Given the evidence on the size of the involvement of international investors in the food, beverage, and tobacco industries, the public health community needs to inquire into the impact of the globalisation of capital in those areas. More research is needed to understand ownership structures, strategies for market expansion, and the extent to which profits are maximised at the cost of health.

Institutional investors will play a crucial role in that regard. This is why the WHO Independent Commission on NCDs proposed to initiate a ‘health forum for investors’ at the WHO. Such a forum would aim to encourage shifts towards investments in healthier portfolios that “include attention to agriculture and food production, the introduction of health and nutrition impact measures of investments, and the role of public investments to shape private investments.”

References


† Institutional holdings in the total market (excluding the financial industry) was almost 50% in the US whereas in emerging economies and Europe the figures were about 13% and 30% respectively. The global average was around 22%.